Changing Paradigm of First Line Therapy in Locally Advanced Metastatic Bladder Cancer

Parminder Singh, MD, presented “Changing Paradigm of First Line Therapy in Locally Advanced Metastatic Bladder Cancer” during the 31st Annual Perspectives in Urology: Point-Counterpoint, on October 18, 2024, in Scottsdale, Arizona.

How to cite: Singh, Parminder. “Changing Paradigm of First Line Therapy in Locally Advanced Metastatic Bladder Cancer.” October 18, 2024. Accessed Feb 2025. https://grandroundsinurology.com/changing-paradigm-of-first-line-therapy-in-locally-advanced-metastatic-bladder-cancer/

Changing Paradigm of First Line Therapy in Locally Advanced Metastatic Bladder Cancer – Summary

Parminder Singh, MD, explores the rapidly evolving treatment landscape for bladder cancer, emphasizing advancements over the past decade. Dr. Singh begins this 12-minute presentation by contextualizing the swift pace of innovation, contrasting historical technological revolutions with the acceleration seen in medical treatments today. 

Dr. Singh addresses the significant shift from evaluating cisplatin eligibility to broader chemotherapy eligibility, given the versatility of the EV-pembrolizumab combination. Dr. Singh further delves into the role of precision medicine, discussing FGFR3 mutations and HER2-positive tumors, which open doors to erdafitinib and trastuzumab therapies, respectively.

About the 31st Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.